Which antimicrobial drug is suitable for treatment of both tuberculosis and leprosy? ?->(Show Answer!)

1. Which antimicrobial drug is suitable for treatment of both tuberculosis and leprosy?

Answer: Rifampicin

Reply

Comments

Tags

Show Similar Question And Answers

QA->Which antimicrobial drug is suitable for treatment of both tuberculosis and leprosy?....

QA->SunPharma has signed an agreement with International Centre for GeneticEngineering and Biotechnology (ICGEB) for clinical development of India’s firstvaccine for the treatment of dengue. What is the name of that drug?....

QA->WHICH DRUG IS KNOWN AS WONDER DRUG....

QA->In a club 70% members read English news papers and 75% members read Malayalam news papers, while 20% do not read both papers. If 325 members read both the news papers, then the total numbers in the club is .........?....

QA->Leprosy should be treated for a minimum period of :....

MCQ->Which one of the following antimicrobial drugs is suitable for treatment of both tuberculosis and leprosy?...

MCQ->Consider the following statements in regard to aerobic and anaerobic treatment processes :1. Biomass production in the aerobic treatment process is more as compared to the anaerobic treatment process.2. Start-up period is more in the aerobic treatment process as compared to the anaerobic treatment process.3. Energy consumption and production is more in the aerobic treatment process as compared to the anaerobic treatment process.Which of the statements given above is/are correct ?...

MCQ->A doctor has decided to prescribe two new drugs D1and D2 to 200 heart patients such that 50 get drug D1, 50 get drug D2 and 100 get both. The 200 patients are chosen so that each had 80% chance of having a heart attack if given neither of the drugs. Drug D1 reduces the probability of a heart attack by 35 %, while drug D2 reduces the probability by 20%. The two drugs when taken together, work independently. If a patient, selected randomly from the chosen 200 patients, has a heart attack then the probability that the selected patient was given both the drug is:...

MCQ-> Throughout human history the leading causes of death have been infection and trauma, Modem medicine has scored significant victories against both, and the major causes of ill health and death are now the chronic degenerative diseases, such as coronary artery disease, arthritis, osteoporosis, Alzheimer’s, macular degeneration, cataract and cancer. These have a long latency period before symptoms appear and a diagnosis is made. It follows that the majority of apparently healthy people are pre-ill.But are these conditions inevitably degenerative? A truly preventive medicine that focused on the pre-ill, analyzing the metabolic errors which lead to clinical illness, might be able to correct them before the first symptom. Genetic risk factors are known for all the chronic degenerative diseases, and are important to the individuals who possess them. At the population level, however, migration studies confirm that these illnesses are linked for the most part to lifestyle factors — exercise, smoking and nutrition. Nutrition is the easiest of these to change, and the most versatile tool for affecting the metabolic changes needed to tilt the balance away from disease.Many national surveys reveal that malnutrition is common in developed countries. This is not the calorie and/or micronutrient deficiency associated with developing nations (type A malnutrition); but multiple micronutrient depletion, usually combined with calorific balance or excess (Type B malnutrition). The incidence and severity of Type B malnutrition will be shown to be worse if newer micronutrient groups such as the essential fatty acids, xanthophylls and falconoid are included in the surveys. Commonly ingested levels of these micronutrients seem to be far too low in many developed countries.There is now considerable evidence that Type B malnutrition is a major cause of chronic degenerative diseases. If this is the case, then t is logical to treat such diseases not with drugs but with multiple micronutrient repletion, or pharmaco-nutrition’. This can take the form of pills and capsules — ‘nutraceuticals’, or food formats known as ‘functional foods’, This approach has been neglected hitherto because it is relatively unprofitable for drug companies — the products are hard to patent — and it is a strategy which does not sit easily with modem medical interventionism. Over the last 100 years, the drug industry has invested huge sums in developing a range of subtle and powerful drugs to treat the many diseases we are subject to. Medical training is couched in pharmaceutical terms and this approach has provided us with an exceptional range of therapeutic tools in the treatment of disease and in acute medical emergencies. However, the pharmaceutical model has also created an unhealthy dependency culture, in which relatively few of us accept responsibility for maintaining our own health. Instead, we have handed over this responsibility to health professionals who know very little about health maintenance, or disease prevention.One problem for supporters of this argument is lack of the right kind of hard evidence. We have a wealth of epidemiological data linking dietary factors to health profiles/ disease risks, and a great deal of information on mechanism: how food factors interact with our biochemistry. But almost all intervention studies with micronutrients, with the notable exception of the omega 3 fatty acids, have so far produced conflicting or negative results. In other words, our science appears to have no predictive value. Does this invalidate the science? Or are we simply asking the wrong questions?Based on pharmaceutical thinking, most intervention studies have attempted to measure the impact of a single micronutrient on the incidence of disease. The classical approach says that if you give a compound formula to test subjects and obtain positive results, you cannot know which ingredient is exerting the benefit, so you must test each ingredient individually. But in the field of nutrition, this does not work. Each intervention on its own will hardly make enough difference to be measured. The best therapeutic response must therefore combine micronutrients to normalise our internal physiology. So do we need to analyse each individual’s nutritional status and then tailor a formula specifically for him or her? While we do not have the resources to analyze millions of individual cases, there is no need to do so. The vast majority of people are consuming suboptimal amounts of most micronutrients, and most of the micronutrients concerned are very safe. Accordingly, a comprehensive and universal program of micronutrient support is probably the most cost-effective and safest way of improving the general health of the nation.The author recommends micronutrient-repletion for large-scale treatment of chronic degenerative diseases because
...

MCQ-> Read the following case – let and answer the question that follow Krishna Reddy was the head of a pharmaceutical company that was trying to develop a new product. Reddy, along with his friend Prabhakar Rao, assessed that such products had mixed success. Reddy and Rao realized that if a new product (a drug) was a success, it may result in sales of 100 crores but if it is unsuccessful, the sales may be only 20 crores. They further assessed that a new drug was likely to be successful 50% of times. Cost of launching the new drug was likely to be 50 crores. Now, Reddy and Rao were in a quandary whether the company should go ahead and market the drug. They contacted Raj Adduri, a common friend for advice. Adduri was of the opinion that given the risky nature of launch, it may be a better idea to test the market. Rao and Reddy realized test marketing would cost 10 crores. Adduri told them the previous test marketing results have been favorable 70% of times and success rate of products favorably tested was 80%.Further, when test marketing results were unfavorable; the products have been successful 30% of the times.How much profit can the company expect to earn if it launches the new drug(suppose there are no additional costs)?
...